Mineralys CEO sells 75,000 shares under trading plan

Mineralys Therapeutics, Inc. Chief Executive Officer Jon Congleton reported open-market sales of a total of 75,000 shares of the company’s Common Stock on March 31, 2026.

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. Chief Executive Officer Jon Congleton reported open-market sales of a total of 75,000 shares of the company’s Common Stock on March 31, 2026. The transactions were executed at weighted-average prices of $25.5006, $26.5385, and $27.0511 per share across multiple trades. These sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 30, 2025. Following the transactions, Congleton directly holds 705,051 shares of Mineralys Therapeutics Common Stock.

Insider Trade Summary 10b5-1

Net Seller: 75,000 shares

Net Sell 3 txns

Insider Congleton Jon

Role Chief Executive Officer

Sold 75,000 shs ($1.97M)

Type	Security	Shares	Price	Value
Sale	Common Stock	19,364	$25.5006	$494K
Sale	Common Stock	55,183	$26.5385	$1.46M
Sale	Common Stock	453	$27.0511	$12K

Holdings After Transaction: Common Stock — 705,051 shares (Direct)

Footnotes (4)

1. F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025.
2. F2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.0000 to $25.9994. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
3. F3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.0000 to $26.9999. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
4. F4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.0000 to $27.1000. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

Key Figures

Total shares sold: 75,000 shares Shares sold tranche 1: 19,364 shares at $25.5006/share Shares sold tranche 2: 55,183 shares at $26.5385/share +3 more

6 metrics

Total shares sold 75,000 shares Common Stock sold in open-market transactions on March 31, 2026

Shares sold tranche 1 19,364 shares at $25.5006/share First reported open-market sale on March 31, 2026

Shares sold tranche 2 55,183 shares at $26.5385/share Second reported open-market sale on March 31, 2026

Shares sold tranche 3 453 shares at $27.0511/share Third reported open-market sale on March 31, 2026

Shares held after transactions 705,051 shares Direct Common Stock holdings following March 31, 2026 sales

Trading plan adoption date December 30, 2025 Rule 10b5-1 trading plan governing the reported sales

Key Terms

Rule 10b5-1 trading plan, weighted-average price, open-market sale

3 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted-average price financial

"The price reported in Column 4 is a weighted-average price."

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MLYS CEO Jon Congleton report?

Jon Congleton reported selling 75,000 shares of Mineralys Therapeutics Common Stock. The open-market transactions occurred on March 31, 2026, at various weighted-average prices between about $25.50 and $27.05 per share under a pre-arranged Rule 10b5-1 trading plan.

At what prices did the MLYS CEO sell his Mineralys shares?

The CEO’s reported sales used weighted-average prices of $25.5006, $26.5385, and $27.0511 per share. Each price reflects multiple trades within narrow ranges, as detailed in the Form 4 footnotes covering the March 31, 2026 transactions.

How many Mineralys (MLYS) shares does the CEO still own after the sale?

After selling 75,000 shares, Jon Congleton directly holds 705,051 Mineralys Therapeutics Common Stock shares. This figure comes from the Form 4 totals listed following the final March 31, 2026 transaction and represents his remaining direct ownership position.

Were the MLYS CEO’s Mineralys stock sales under a Rule 10b5-1 plan?

Yes. The Form 4 states the transactions were effected under a Rule 10b5-1 trading plan adopted on December 30, 2025. Such plans pre-schedule trades, aiming to separate them from day-to-day market timing decisions by the insider.

How many Mineralys (MLYS) share sale transactions did the CEO report?

The Form 4 reports three separate open-market sale entries on March 31, 2026. They cover 19,364 shares, 55,183 shares, and 453 shares, each at different weighted-average prices, totaling 75,000 Mineralys Therapeutics Common Stock shares sold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/02/2026 - 06:54 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Congleton Jon

(Last) (First) (Middle)

150 N. RADNOR CHESTER RD.

SUITE F200

(Street)

RADNOR PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		S(1)		19,364	D	$25.5006(2)	760,687	D
Common Stock	03/31/2026		S(1)		55,183	D	$26.5385(3)	705,504	D
Common Stock	03/31/2026		S(1)		453	D	$27.0511(4)	705,051	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025.

2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.0000 to $25.9994. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.0000 to $26.9999. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.0000 to $27.1000. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

Remarks:

	/s/ Adam Levy, Attorney-in-fact	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)